In addition, it was shown that EZH2 suppression ameliorate intestinal inflammation and delay the onset of colitis associated cancer, suggesting the feasibility of EZH2 inhibitor for the control of IBD (74). This evidence concerns the gene EZH2 and inflammatory bowel disease.